Intra-op Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent Ligand

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01511055
Recruitment Status : Terminated (Accrual temporarily suspended, followed by study closure due to technical problems with investigational camera.)
First Posted : January 18, 2012
Last Update Posted : June 8, 2015
Information provided by (Responsible Party):
Sean C. Dowdy, Mayo Clinic

Brief Summary:

Prognosis for many carcinomas, including ovarian carcinoma, is dependent on a complete surgical resection, also known as a R0 resection. At present, the ability to perform a complete resection with negative margins is limited by the surgeon's ability to palpate and visualize the tumor and its margins. Therefore, in order to reduce operative morbidity and costs while maintaining or improving surgical and oncologic outcomes, the investigators must develop technologies that improve visualization of the primary tumor and occult metastases, real time, during surgery. Recent research has demonstrated that the use of fluorescent probes that recognize cancer specific antigens can be used for this purpose when visualized using a prototype near-infrared multispectral imaging system.

This investigation will determine if folate-FITC, a fluorescent probe that recognizes the folate receptor (present in > 90% of ovarian cancers) can facilitate surgical resection and detect tumor nodules not visible to the naked eye.

Condition or disease Intervention/treatment Phase
Ovarian Cancer Drug: EC-17 Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 21 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Phase II, Prospective, Non-Randomized Trial Investigating the Intra-Operative Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent Ligand
Study Start Date : January 2012
Actual Primary Completion Date : June 2014
Actual Study Completion Date : June 2014

Arm Intervention/treatment
Experimental: Folate-FITC Drug: EC-17
One-time dose of Folate-FITC (EC-17), 0.1mg/kg IV 2-3 hours prior to surgery.
Other Name: Folate-FITC

Primary Outcome Measures :
  1. Sensitivity and specificity of intra-operative imaging using Folate-FITC for identification of ovarian cancer metastatic to the peritoneum and lymph nodes [ Time Frame: 1 week ]
    A maximum of 5 nodules less than 1cm in size will be identified in each patient with the naked eye and then visualized with the camera. The nodules will be biopsied after determining if they are fluorescent positive or negative (F+ or F-), and examined microscopically to confirm if carcinoma is present. Up to 5 F+ lesions that were not identified with the naked eye will also be biopsied and examined microscopically to determine if carcinoma is present. These data will establish the sensitivity and specificity of this technique using microscopic analysis as the gold standard.

Secondary Outcome Measures :
  1. Confirmation of low to absent rates of significant adverse events following a one-time dose of folate-FITC (EC-17). [ Time Frame: Duration of hospitalization with a maximum of 7 days ]
    Subjects will be followed and all adverse events will be captured for the duration of hospitalization following administration of investigational product, up to a maximum of 7 days following IP administration and surgical procedure.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Women who are:

  • Diagnosed with or at high clinical suspicion of primary ovarian cancer by either radiologic imaging or physical examination or biopsy or serum tumor markers
  • Scheduled to undergo surgical cytoreduction via laparotomy
  • At least 18 years of age
  • Capable and willing to provide informed consent

Exclusion Criteria:

Women with:

  • Known sarcomatous histologies
  • Recurrent ovarian cancer
  • Planned surgical approach via laparoscopy or robotic surgery
  • A history of anaphylactic reactions to Folate-FITC or insects
  • Inability or unwillingness to provide informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01511055

United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Principal Investigator: Sean C Dowdy, MD Mayo Clinic

Responsible Party: Sean C. Dowdy, Associate Professor - Obstetrics and Gynecology, Mayo Clinic Identifier: NCT01511055     History of Changes
Other Study ID Numbers: 11-002980
First Posted: January 18, 2012    Key Record Dates
Last Update Posted: June 8, 2015
Last Verified: June 2015

Keywords provided by Sean C. Dowdy, Mayo Clinic:
Ovarian Cancer

Additional relevant MeSH terms:
Ovarian Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Genital Neoplasms, Female
Urogenital Neoplasms
Adnexal Diseases
Genital Diseases, Female
Endocrine System Diseases
Gonadal Disorders
Folic Acid
Vitamin B Complex
Growth Substances
Physiological Effects of Drugs